Literature DB >> 7428678

Glucocorticoid effects on lipid metabolism in HeLa cells: inhibition of cholesterol synthesis and increased sphingomyelin synthesis.

D Johnston, E R Matthews, G Melnykovych.   

Abstract

Glucocorticoid treatment had a variety of effects on lipid composition of HeLa S3G (HeLa 65) cells. Total cellular cholesterol levels were lower in treated cultures than in controls within 6 h of the addition of glucocorticoids and remained lower for up to 48 h. Total cell protein and total lipid phosphorus levels were also decreased, but only after more prolonged exposure. The major phospholipid components, viz. phosphatidylcholine and phosphatidylethanolamine, representing, respectively, 48% and 29% of the total phospholipids, were not affected by glucocorticoid treatment. Sphingomyelin, however, increased from 4.8 to 8.3% of the total phospholipid content after 48 h of exposure, whereas lysolecithin increased from 0.1 to 1.9%. The incorporation of labeled precursors was also measured after glucocorticoid addition. As related to cellular protein content, only slight increases were found for all major phospholipids. In contrast, sphingomyelin synthesis increased up to 200% after treatment with glucocorticoids. The fatty acid and plasmalogen compositions were unchanged by glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7428678     DOI: 10.1210/endo-107-5-1482

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Fluorescence image screening for chemical compounds modifying cholesterol metabolism and distribution.

Authors:  Reiko Ishitsuka; Tamio Saito; Hiroyuki Osada; Yoshiko Ohno-Iwashita; Toshihide Kobayashi
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

Review 2.  How is the level of free arachidonic acid controlled in mammalian cells?

Authors:  R F Irvine
Journal:  Biochem J       Date:  1982-04-15       Impact factor: 3.857

Review 3.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  Altered sterol synthesis and its relationship to fluid-phase endocytosis in a macrophage cell line P388D1.

Authors:  S C Miller; G Melnykovych
Journal:  In Vitro       Date:  1983-11

5.  Dexamethasone modulates rat renal brush border membrane phosphate transporter mRNA and protein abundance and glycosphingolipid composition.

Authors:  M Levi; J A Shayman; A Abe; S K Gross; R H McCluer; J Biber; H Murer; M Lötscher; R E Cronin
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Phosphatidylcholine as the choline donor in sphingomyelin synthesis.

Authors:  C M Eppler; B Malewicz; H M Jenkin; W J Baumann
Journal:  Lipids       Date:  1987-05       Impact factor: 1.880

7.  The inhibition of diacylglycerol-stimulated intracellular phospholipases by phospholipids with a phosphocholine-containing polar group. A possible physiological role for sphingomyelin.

Authors:  R M Dawson; N Hemington; R F Irvine
Journal:  Biochem J       Date:  1985-08-15       Impact factor: 3.857

8.  Metabolic reprogramming of inner ear cell line HEI-OC1 after dexamethasone application.

Authors:  Michel Kather; Sabine Koitzsch; Bernhard Breit; Stefan Plontke; Bernd Kammerer; Arne Liebau
Journal:  Metabolomics       Date:  2021-05-24       Impact factor: 4.290

9.  High lateral mobility of endogenous and transfected alkaline phosphatase: a phosphatidylinositol-anchored membrane protein.

Authors:  M Noda; K Yoon; G A Rodan; D E Koppel
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

10.  Serum cholesterol selectively regulates glucocorticoid sensitivity through activation of JNK.

Authors:  Nan Yang; Giorgio Caratti; Louise M Ince; Toryn M Poolman; Peter J Trebble; Cathy M Holt; David W Ray; Laura C Matthews
Journal:  J Endocrinol       Date:  2014-08-26       Impact factor: 4.286

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.